AstraZeneca Archives

astrazeneca acerta pharma acquitision leukemia myeloma oncology cancer1

News and Trends 21 Dec 2015

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Acerta Pharma is an elusive Netherlands based Biotech with pipelines in Blood cancer and solid tumors which has somehow wrangled the biggest Biotech deal of 2015 with Pharma Giant AstraZeneca. Acerta Pharma is a Biotech start-up founded in 2012 which combines two technology platforms in drug discovery and development with a broad target range, from […]

December 21, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 1 Sep 2015

Genentech’s Sean Bohen defects to AstraZeneca as CMO

AstraZeneca‘s Senior management team gets reinforced by Sean Bohen, a top executive from Roche‘s subsidiary Genentech. Starting in two weeks, he will push late-stage treatments to the market. It’s been two months since two senior manager left the struggling AstraZeneca. Among them, Briggs Morrison, who left to become new CEO of Syndax. To replace him, […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

AstraZeneca Adds New Antisense Drugs to its Pipeline

Isis Pharmaceuticals and AstraZeneca extend their collaboration to discover and develop antisense therapies. After cancer, the partners are now targeting cardiovascular, metabolic and renal diseases. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 28 Jul 2015

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

The Pharma giant AstraZeneca is still struggling even if in better shape. It just sold one of his rare disease drug already on the market to THE rare disease Biotech Genzyme, now part of Sanofi. AstraZeneca is under pressure. Last April 2015, the company reported a fall in revenues and profits (7% lower than previous […]

July 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 31 May 2015

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

The big pharma companies Eli Lilly and AstraZeneca will combine two of their cancer drugs to make the perfect cocktail against solid tumors. They have entered a clinical collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor (MEDI4736), in combination with Cyramza (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. MEDI4736 is […]

May 31, 2015 - 2 minutesmins - By Julie Lellouche

Orca Pharmaceuticals AstraZeneca autoimmune2

News and Trends 27 Feb 2015

Orca Pharmaceuticas Associates with AstraZeneca to Identify Best-in-Class RORγ Inhibitors

Orca Pharmaceuticals, and AstraZeneca embarked on a three year collaboration to develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (RORγ). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, orally available and effective treatment. RORγ plays a key role in […]

February 27, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Sep 2014

New Collaboration for New Cancer Therapies

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca, has entered into a collaboration to establish a joint lab in Cambridge, UK, with Cancer Research Technology, the commercial arm of Cancer Research UK. The new laboratory will be the first partnership of its kind of both organizations, and will focus on […]

September 30, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us